SSRIs treatment did not completely restore affective state in patients with the initial clinically confirmed major depressive disorder/generalized anxiety disorder after COVID-19 disease

• Published in: European psychiatry 2022-06, Vol.65 (S1), p.S96-S96
• Main Authors: Fedotova, J., Bereza, Z.
• Format: Article
• Language: English
• Subjects: Abstract; anxiety; Coronaviruses; COVID-19; depression; Generalized anxiety disorder; Mental depression; Oral Communication; pharmacotherapy; Severe acute respiratory syndrome coronavirus 2; SSRIs; Women
• ISSN: 0924-9338; 1778-3585
• DOI: 10.1192/j.eurpsy.2022.279

IntroductionThe major clinical outcomes of COVID-19 in the brain are associated with its deleterious neurological and mental health actions.Today, there are limited findings concerning the studying of neuropsychiatric action for SARS-Cov-2 in humans after COVID-19 disease.ObjectivesThe aim of the present study was to compare the efficacy of SSRIs (escitalopram, sertraline and fluoxetine) for 6 months therapy on the affective profile of man and women with the clinically confirmed Major Depressive Disorder (MDD) or Generalized Anxiety Disorder (GAD) cases following COVID-19 disease.Methods. For the assessment of affective profile in man and women (30-55 years) with the initial clinically confirmed MDD or GAD cases after COVID-19 disease, we used the different tests: Montgomery-Asberg Depression Rating Scale (MADRS) and anxiety scale (ShARS Scale). The hormonal and monoamines levels in the serum blood were measured by ELISA tests before and after SSRIs therapy.ResultsAfter 6 months of SSRIs therapy, MADRS Scale showed a incomplete disappearance of the depressive/anxiety manifestations in both men and women with the initial clinically confirmed MDD case after COVID-19 (p